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Background: To evaluate the cost-effectiveness of growth hormone (GH) treatment (Genotropin®) compared with
no GH treatment in adults with GH deficiency in a Swedish societal setting.
Methods: A Markov-type cost-utility simulation model was constructed and used to simulate, for men and women,
morbidity and mortality for GH-treated and -untreated individuals over a 20-year period. The calculations were
performed using current available prices concerning morbidity-related healthcare costs and costs for Genotropin®.
All costs and treatment effects were discounted at 3%. Costs were expressed in Euro (1€ = 9.03 SEK). GH-treated
Swedish patients (n = 434) were identified from the KIMS database (Pfizer International Metabolic Database) and
untreated patients (n = 2135) from the Swedish Cancer Registry and the Hospital Discharge Registry.
Results: The results are reported as incremental cost per quality-adjusted life year (QALY) gained, including both
direct and indirect costs for GH-treated versus untreated patients. The weighted sum of all subgroup incremental
cost per QALY was €15,975 and €20,241 for men and women, respectively. Including indirect cost resulted in lower
cost per QALY gained: €11,173 and €10,753 for men and women, respectively. Key drivers of the results were
improvement in quality of life, increased survival, and intervention cost.
Conclusions: The incremental cost per QALY gained is moderate when compared with informal thresholds applied
in Sweden. The simulations suggest that GH-treatment is cost-effective for both men and women at the €55,371
(SEK 500,000 – the informal Swedish cost-effectiveness threshold) per QALY threshold.
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Growth hormone deficiency (GHD) in adults with hypo-
pituitarism can persist from childhood or can be ac-
quired in adulthood, most often as a result of pituitary
or peripituitary tumours or their treatment. The Society
for Endocrinology (UK) estimates the prevalence of
GHD in the adult population to be three in 10,000 [1],
which equates to approximately 2700 adults in Sweden.
Adults suffering from GHD are typically characterised
by impaired health-related quality of life (QoL) along
with increased risks of cardio- and cerebrovascular mor-
bidity [2] and mortality [3,4]. The most affected QoL do-
mains are energy levels, vitality, life-drive, emotional* Correspondence: Kristian.Bolin@economics.gu.se
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reproduction in any medium, provided the orfunctioning, social isolation, and cognitive abilities such
as memory [5]). A study based on data collected prior to
the introduction of growth hormone treatment (GHT)
showed that additional healthcare costs resulting from
GHD in Sweden were estimated to be SEK 36,000 (ap-
proximately €3,987) per patient and year [6]. Patients
with untreated GHD consumed more healthcare re-
sources (doctor visits and hospital stays) compared with
the general population. Patients with GHD were also
more frequently absent from work due to sickness and
more likely to claim disability pension compared with
the general population [6,7]. Similar results have been
found for other countries [8,9].
Growth hormone therapy (GHT) in adults with GHD
has been shown to improve QoL [10-12] and to reduce
cardio- and cerebrovascular morbidity [13,14]. Ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Markov structure for cost-effectiveness model. Possible
transitions are indicated by arrows. Diseases considered: CHD, coronary
heart disease.
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also reduces mortality [15]. The increases in drug cost
associated with the introduction of GHT have therefore
been offset by a reduction in healthcare utilisation and
less sickness absenteeism [16,17].
Cost-effectiveness analysis of health technologies are
becoming a pre-requisite for healthcare decision-making
in many countries. The peer-reviewed literature address-
ing the cost-effectiveness of GHT in adults is lacking
[18,19] and limited to only one publication in the past
decade, based on an analysis of the cost-effectiveness of
GH on behalf of the National Institute for Clinical Excel-
lence (NICE) in UK [19]. The objective of this paper was
to evaluate the cost-effectiveness of GHT compared with
no GHT in adults suffering from GHD, using Swedish
data, based on treatment effects, morbidity, mortality
and costs. As the present study was performed from the
societal perspective, both direct and indirect costs were
taken into consideration. We calculated the cost-
effectiveness of GHT by including cardiovascular mor-
bidity and mortality assessments as well as novel
methods to evaluate economic impact of QoL data.
Methods
In this section we will specify the methods that have
been used for the analysis. At the end of the section a
shortlist of assumptions is provided.
Subjects
Patients in the GHT group were identified from the
KIMS (Pfizer International Metabolic Database) [20]—
434 of the 1459 Swedish patients identified from KIMS
met the following inclusion criteria and were included in
the analysis: (1) Resided in Sweden; (2) GHD due to
non-functioning pituitary adenoma (NFPA); (3) not re-
ceiving GHT for ≥6 months prior to entry into the data-
base; (4) no missing QoL values at baseline; and (5) aged
>18 years at entry into KIMS. The study period was
from 1995–2011 and the GHT prescribed was
Genotropin®.
In the untreated group, patients diagnosed with pituitary
adenoma were identified through the Swedish Cancer
Registry and the Hospital Discharge Registry administered
by The National Board of Health and Welfare. Patients
(n = 2135) aged 18–75 years were included in the analysis;
the study period was from 1987–1992. Eighty percent of
patients had undergone surgical removal of the
macroadenoma, therefore it was assumed that the major-
ity of patients suffered from macroadenomas, which are
associated with a high incidence of concomitant pituitary
failure [21]. Patients with acromegaly, Cushing’s disease,
or malignant pituitary adenoma, and patients who had
died within 1 month after diagnosis of pituitary adenoma
were excluded. Permission to use the registry data onpituitary tumours in Sweden was granted by the ethics
committee of the Karolinska Institute.
Simulation model
A simulation model was constructed to assess the cost-
effectiveness of GHT in patients with GHD due to
NFPA. The model is a Markov-type simulation model
that tracks a cohort of patients over 20 years. Each year
(cycle) the population is at risk of moving into specific
states of illness or death. The proportion of patients that
moves from one state to another was calculated on given
age- and gender-specific cardio- and cerebrovascular
morbidity and mortality rates. The model performs simul-
taneous but separate calculations for a population that re-
ceived GHT and a population that did not receive GHT.
(See Additional file 1 for more details on the calculation).
The model distinguishes between six health states, de-
fined as follows: (a) no morbidity; (b) new coronary heart
disease (CHD) event; (c) previous CHD event; (d) new
stroke; (e) previous stroke; and (f) dead (Figure 1). The
model does not allow for transition from one morbidity
state to any other state except death; neither does it allow
for more than one event per cycle. However, it is possible to
have a new CHD or stroke event, respectively. The model
distinguishes between different patient groups based on: (1)
gender; (2) age (18–30 yr, 31–54 yr, 55–65 yr, and ≥66 yr);
and (3) QoL–Assessment of Growth Hormone Deficiency
in Adults (QoL-AGHDA) (<2, 2–6, 7–11, 12+) score at
baseline, resulting in calculations being performed for 32
different patient groups, and six health states.
Data used in the model
The simulation model was provided with the following in-
put: (1) cerebro- and cardiovascular morbidity and mortal-
ity risks for GHT and untreated patients; (2) QoL as
measured by the QoL-AGHDA before the start of GHT
(at baseline) and after 1 year of GHT; (3) average annual
direct healthcare costs caused by disease (CHD and
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unit cost); (5) cost of sick leave; and (6) average net contri-
bution to society (production minus consumption).
Cerebro- and cardiovascular morbidity and mortality risks
Morbidity and mortality data was obtained from the
Swedish hospital discharge and causes of death regis-
tries, respectively, for the untreated patients and from
the KIMS database for the GHT patients. Relative mor-
bidity and mortality risks were calculated according to
age and gender groups (Table 1). A further division of
risks based on QoL was not possible because there were
no QoL data for the untreated group. Therefore, the
number of individuals in each state and at each point in
time does not differ according to QoL in the model.
Mean age was 54 years and 53 years in the GHT and un-
treated groups, respectively, but the difference was not
statistically significant. Mean time of observation was
higher in the GHT group (6 yr) as compared with the
untreated group (5.5 yr) and the difference was signifi-
cant (P < 0.003). Each group had a similar proportion of
men and women (54% and 51% male for the treated and
untreated groups, respectively).
Quality of life as measured by QoL-AGHDA
Prior to initiation of GHT, patients in the KIMS data-
base completed the QoL-AGHDA questionnaire [22],
which is a disease-specific measure of QoL for adults
with GHD. A validated questionnaire with good reliabil-
ity and a high level of internal consistency [23], QoL-
AGHDA consists of 25 items that evoke yes/no (=1/0)
answers to specific problems; the sum of yes (=1) an-
swers constitutes the QoL-AGHDA score. A high QoL-
AGHDA score denotes a poor QoL. A Swedish version





18–30 0 0 0
31–54 0.0044 0.0045 0.0044
55–65 0.0118 0.0281 0.0074
65+ 0.0185 0.0408 0.0123
Women, years
18–30 0 0 0
31–54 0.0022 0.0055 0.0011
55–65 0.0045 0.0145 0.0067
65+ 0.0046 0.0306 0.0183
CHD, coronary heart disease; GHD, growth hormone deficiency.
Sources of data: Swedish hospital discharge and causes of death registries (untreatedual translation panels during the measure development.
Although the QoL-AGDHA questionnaire does not pro-
vide preference-based assessments of individual health
applicable for economic decision-making, the QoL-
AGDHA score was translated into EQ-5D scores, a gen-
eric measure of QoL, (EuroQoL Group, Rotterdam, The
Netherlands) by applying an algorithm recently derived
specifically for the Swedish population (see Additional
file 1 for more detail) [24]. Average QoL-AGDHA scores
at baseline and average treatment effects (reduction in
the QoL-AGDHA score) for each subgroup were calcu-
lated based on the KIMS patient group. For the case sce-
nario at baseline, it was assumed that the treatment
effect (reduction in QoL-AGDHA score) resulting from
GHT appeared within the first year of treatment. For
subsequent years (years 2–20), utility-score changes
were induced by advancing age. The comparative popu-
lation that did not receive GHT was assumed to have
the same baseline QoL-AGDHA scores as the treated
population, but no first-year treatment effect.
Average annual direct healthcare costs caused by disease
(CHD and stroke)
Direct cost estimates were morbidity-related healthcare
cost data that included both inpatient and outpatient
care. The data were collected from a county in southern
Sweden (Region of Skåne) that is considered demo-
graphically representative of the Swedish population.
Healthcare costs during the first year of disease were
distinguished from those costs incurred in the subse-
quent years after diagnosis and as a result of the disease.
The cost estimates were based on Swedish individual
diagnosis-related data on all inpatient stays and outpatient
visits [25], which were inflated to 2011 year price levels












d); KIMS database (treated).
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with CHD or stroke was followed during a 3-year period.
The average cost during the first year following initial
diagnosis was used as an estimate of the first-year
healthcare cost: €5,331 (SEK 48,135) and €8,729 (SEK
78,824) for CHD and stroke, respectively; the average cost
during the second and third years was used as an estimate
of the healthcare costs during subsequent years: €1,528
(SEK 13,799) and €2,095 (SEK 18,915) for CHD and
stroke, respectively. Cost of physician (specialist) visits was
€373 (SEK 3,367).
Intervention costs
The intervention cost is the cost of GHT (Genotropin®),
i.e. the amount of utilisation (dose) × the unit cost €31
(SEK 282) per milligram (the Swedish Dental and Pharma-
ceutical Benefits Agency). Information of the mean con-
sumption of Genotropin® per year for each of the age,
gender and QoL-AGDHA (baseline) groups was provided
from the study population in the KIMS database (Table 2).
Cost of illness-related absenteeism
The simulation model takes into account two different
sources of indirect costs: changes in illness-relatedTable 2 Estimated age-specific QoL-AGHDA score at baseline,






















aThere was no observation in this group.
Qol-AGHDA, Quality-of-Life Adult Growth Hormone Deficiency Assessment.
Sources of data: KIMS database.absenteeism and cost resulting from indirect effects due to
difference in mortality. Evaluations are based on the hu-
man capital approach [26]. Information concerning reduc-
tion in illness-related absenteeism was taken from Jonsson
et al. [7], where sick leave and early pension was studied in
a Swedish population for the year 1989. Patients included
in the National Cancer Registry who were diagnosed before
the end of 1989, alive in 1989, and aged 16–64 years, were
selected for the study. A total of 809 individuals remained
eligible for analysis and the Swedish National Social Insur-
ance Board was able to supply data on sick leave and dis-
ability pension status for 803 and 802 of these patients,
respectively. The average number of reimbursed sick days
was 40.2 among the untreated patients and 24.0 in the con-
trol group, resulting in a gain of 16 workdays for GHT pa-
tients. The gain was assumed to be the same between all
groups below the age of 65 years, and over time. The value
of the production resulting from a workday was estimated
using average labour income in Sweden 2011: €182 (SEK
1644) (Statistics Sweden, www.scb.se).
Average net contribution to society
The effect of reduced mortality is determined by the
position in the person’s lifecycle. Before the age offirst-year treatment effect, and drug utilisation
Women Drug dosage (mg/day)
Baseline 1st-year treatment Men Women
14.60 −5.48 0.30 0.22
16.57 −5.48 0.26 0.36
17.13 −4.25 0.23 0.29
14.20 −2.00 0.39 0.25
8.67 −2.33 0.24 0.25
8.64 −2.65 0.23 0.33
8.21 −2.44 0.23 0.28
9.17 −4.42 0.25 0.21
4.00 0 0.54 0.18
4.17 −1.81 0.30 0.44
3.92 −1.60 0.28 0.25
4.14 −1.67 0.24 0.25
1.00 −1.00 0.41 0.26
0.40 0 0.34 0.43
0.14 0 0.28 0.30
0.67 0.5 0.18 0.23
Table 3 Growth hormone treatment versus no treatment:
outcomes over a 20-year period (weighted averages)
Outcomes Men Women
Life-years gained 2.3 2.1
Incremental QALY 2.3 2.3
Incremental costs, €, including direct costsa 31,872 41,096
Incremental costs, €, including direct and indirect costsa,b 24,607 28,570
Incremental cost per QALY, € (excludes indirect costsb) 15,975 20,241
Incremental cost per QALY, € (includes indirect costsb) 11,173 10,753
Incremental cost per QALY, € (excludes all indirect effects) 48,252 46,601
aDirect costs = treatment cost minus avoided healthcare costs.
bIndirect costs = cost of sickness-related absenteeism + lost value of
production (production minus consumption due to increased mortality).
GHD = growth hormone deficiency; QALY = quality-adjusted life years.
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minus consumption) is positive and is negative there-
after. Estimates of the net values were taken from
Ekman [27], using the best age-match.
Cost-effectiveness outcomes
Outcomes, for men and women respectively, are presented
as the weighted sum of all subgroup incremental costs,
life-years gained (LYG), quality-adjusted life year (QALY)
gained, and incremental cost per QALY gained, denoted as
incremental cost-utility ratio (ICUR). The weights are the
relative population-share of each of the 32 groups taken
from the KIMS population used in this study. For com-
parative reasons, results both excluding (base case) and in-
cluding indirect costs are presented. In the analysis, both
costs and effects were discounted at a 3% rate.
Sensitivity analyses
All data are subject to uncertainties, either as a conse-
quence of measurement errors or as a result of stochas-
tic variation (variation around the mean) of the
underlying variables. In order to assess the extent to
which the results were sensitive to the various assump-
tions, the ICUR was re-estimated for a 1000 set of input
values drawn from a probability distribution. The choice
of variables that were allowed to vary was decided by a
deterministic pre-analysis that identified the variables to
which the results were most sensitive. Both univariate
and bivariate, non-stochastic, as well as stochastic, sensi-
tivity analyses were performed. The non-stochastic sen-
sitivity analyses examined ranges of specific variables,
e.g. intervention costs and first-year treatment effects, in
which the ICUR falls below a specified threshold value.
Based on the constructed simulation model, Monte
Carlo simulations of the incremental cost-utility ratio
were performed, using information concerning the dis-
tribution and its characteristics for the key parameters
entered in the calculation of the ICUR. The stochastic
sensitivity analysis included Monte Carlo simulations re-
garding five variables (variation in subgroups is analysed
separately): (1) QoL-AGDHA scores at baseline (as-
sumption: normal distribution); (2) intervention cost
(drug utilisation) (assumption normal distribution); (3)
yearly mortality risks (assumption: beta distribution); (4)
morbidity-related healthcare costs (assumption: log-
normal distribution); and (5) first-year treatment effect
(assumption: normal distribution). In each case, the
point-values used in the deterministic calculations - see
Tables 1 and 2 - were used as mean values for the prob-
ability distribution. The standard deviations were as-
sumed to be 0.2 times the corresponding mean value for
all variables. In addition, we performed simulations as-
suming a considerably higher relative standard deviation
of mortality risks (0.005 for all groups). The method formaking models probabilistic follows Briggs et al. [28]
(see Additional file 1).
Short list of modelling assumptions
The following assumption were made in the calculations:
(1) populations: untreated patients during the period
1987–1992 were assumed to be identical to the
treated patients from the period 1995–2011 in all
respects (but GH treatment);
(2) time-paths: all patients were assumed to fulfil the
Markov-assumption in that the likelihood of future
events depends only on current state;
(3) co-morbidities: cardio- and cerebrovascular diseases
were assumed to capture the extent to which GHD
patients suffer from co-morbidities related to their
GHD;
(4) multiple health states: it was assumed that there is
no transition between co-morbidity states.
(5) mortality risks: assumed to differ between age and
gender groups, but to be equal across QoL-AGDHA
states;
(6) treatment effects: assumed to occur during the first
year. Change in QoL-AGDHA in subsequent years
are due to ageing.
(7) indirect costs: It was assumed that sickness-absenteeism
is equal between Qol-AGDHA states.
Results
The results of the simulation model showed a reduction
in mortality and an improvement in QoL associated with
GHT as compared with no treatment. The mean incre-
mental LYG for patients who received GHT compared
with no treatment was 2.3 and 2.1 for men and women,
respectively. The average gain in QALY with GHT was
2.3 and 2.3 in men and women, respectively (Table 3).
The per-patient total weighted sum of all incremental
net costs (treatment cost minus avoided healthcare
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€31,872 and €41,096 for men and women, respectively.
Including indirect costs, the corresponding figures were
€24,607 and €28,570. For GHT, drug costs were offset by
lower direct healthcare costs (due to fewer CHD and stroke
events) and lower indirect costs due to less sickness-related
absenteeism. Indirect costs resulting from reduced mortality
increased the net cost of GHT due to an on-average nega-
tive net contribution to society (value of production minus
value of consumption) among the additional survivors. The
net per-patient cost (cost of GHD treatment minus changes
in cost of general healthcare) increased for both men and
women when the costs from reduced sickness-related ab-
senteeism and mortality were taken into account.
The estimated incremental costs per QALY were
€15,975 (men) and €20,241 (women) when including
only intervention and healthcare costs. Including all in-
direct costs, the incremental costs per QALY gained
were lower; €11,173 and €10,753 for men and women,
respectively.
The probabilistic sensitivity cost-effectiveness accept-
ability curves (Figure 2) suggest that the GH-treatment
has a 100% probability of being cost-effective for both
men and women at the €55,371 (SEK 500,000) per
QALY threshold, which is the threshold level considered
to be moderate for society’s willingness to pay for an
additional QALY in Sweden [29]. Moreover, the esti-
mated cost-effectiveness ratio varied among the different
subgroups. This is illustrated in Figure 3. No significant
changes in the results were obtained for the alternative
mortality-risk specification.
Non-stochastic sensitivity analysis showed results were
most sensitive to changes in intervention costs and first-
year treatment effect. Reasonable variations in these var-
iables did not produce an ICUR above the threshold
value €55,371 (SEK 500,000) for men and women. Simi-
larly, the stochastic sensitivity analysis produced no
value of the cost-utility ratio above €55,371.Figure 2 Cost-effectiveness acceptability curves for men and women.
QLAY (horisontal axis), the likelihood (vertical axis) that GH treatment is cosDiscussion
In this study, a simulation-model–based cost-effectiveness
analysis was conducted comparing GHT with no GHT in
adults with GHD in Sweden. The estimated incremental
cost-effectiveness ratios ranged between €10,753 to
€20,241, which is below the threshold level of €55,371 (SEK
500,000) considered moderate for society’s willingness to
pay for an additional QALY in Sweden [29]. Compared
with thresholds inferred from the literature, this study’s es-
timates are substantially lower than those found in Kenkel
[30] who reported a willingness to pay for a QALY in the
range $74,000 to $450,000, and within the range reported
by King et al. [31] of $12,500 and $32,200 (2011:1 USD =
0.72 €). Our estimated incremental cost per additional
QALY gained suggests that GHT is cost-effective.
Previously, only two studies had been conducted to
evaluate the cost-effectiveness of GHT [18,19]. The most
recent assessment by Bansback et al. [19], part of the
NICE Technology Appraisal [32], estimated the incre-
mental cost per QALY gained to be about £50,000,
pertaining to the year 2002 in England and Wales. The
methodology used in our study differed from that used
by Bansback et al. with respect to: (1) the incorporation
of mortality; (2) the incorporation of indirect effects
working through sickness-related absenteeism and the
values of productivity and consumption in the economy
(arising from mortality); and (3) the method for inferring
QALY weights from treatment effects. Moreover, the
analysis of our study employed a Markov-type cohort
model using transition probabilities from a Swedish popu-
lation, while Bansback et al. simulated morbidity and
mortality events in a population using the Framingham
risk equations [33], which link cardiovascular events to in-
dividual characteristics that, in turn, are influenced by
GHT. However, the Framingham risk equations have not
been validated for GHD.
The main explanation for our estimates being consid-
erably lower than those published by Bansback et al.Each curve indicates, for a specific willingness-to-pay for an additional
t-effective, compared to no treatment.
Figure 3 Cost-effectiveness ratios per QOL-AGDHA group and men and women. Each graph shows the cost-effectiveness ratio (vertical axis)
as a function of the QOL-AGDHA score (horisontal axis).
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work absenteeism). Mortality had virtually no effect on
the estimated cost-effectiveness ratios in Bansback et al.,
implying very small differences in mortality risk between
treated and untreated patients. Excluding both mortality
and work-absenteeism effects in our model increased the
cost-effectiveness ratios to about €48,252 and €46,601 for
men and women, respectively; hence, in the same range as
the estimates obtained by Bansback et al. However, the lit-
erature suggests that there are significant effects of GHT
on mortality [15], which is supported by the data in our
model. It is noteworthy, however, that there was a dra-
matic change in lipid-lowering treatment regimens in the
early 1990s in Sweden, which could be considered as a
potential confounder. We can speculate that the control
cohort most likely did not receive statins, which resulted
in higher cardiovascular risks than if they had been pre-
scribed appropriate lipid-lowering treatment. In the gen-
eral KIMS population, lipid-lowering drugs are reported
in approximately 18% of the patients. Therefore, we would
not consider the introduction of statins as a confounder.
The influence on cost-effectiveness of changes in the values
of production and consumption produced by mortality and
sickness-related absenteeism was relatively small.
Both this study and Bansback et al. [19] employed
GHD-specific QoL scores (QoL-AGDHA) in order to
calculate utility weights used for obtaining QALYs.
While Bansback et al. achieved this through an indirect
route using three different QoL questionnaires (QoL-
AGHDA, Nottingham Health Profile, and SF-36), we
utilised published information regarding the link be-
tween QoL-AGHDA and EQ-5D in order to calculate
utility weights directly [24].
GHT drug doses used in our calculations distinguished
between both age and QoL-AGHDA score, whileBansback et al. [19] only accounted for differences be-
tween age groups. Drug costs are also likely to be lower
in our calculations since dosing has declined over time,
something that may also explain the difference in cost-
effectiveness found between the various studies.
The reduction in the number of sick days is somewhat
uncertain as we used information for subjects receiving
no treatment compared with the normal population, not
for those treated with growth hormone. However, the re-
duction is similar to the findings in Svensson et al. [17]
and KIMS data from Sweden further indicate that the
number of sick days is low and comparable to the gen-
eral population for those treated with growth hormones
(data on file). Early retirement was not included in the
simulation model, since no comparable information was
available regarding the effect of GHD and GHT on the
risk of being retired at an earlier age. The effect of early
retirement on the cost-effectiveness of GHT is likely to
be considerable, as the cost imposed on society by early
retirement due to GHD has shown to be substantially
higher than the corresponding cost for sickness-related
absenteeism [6].
An important limitation of this study was that the data
used for the simulations were gathered from different
sources. It would be ideal to gather all information from
the same source, but a randomised controlled trial
would not be possible in practice due to ethical consid-
erations. The reliability of the estimates in the study
concerning mortality, treatment effects and treatment
doses could be disputed. With regard to mortality risks,
the data in this study are likely to reflect true differences
between GHT and untreated individuals suffering from
GHD. The information concerning mortality for un-
treated individuals comes from the Swedish causes of
death registry covering all GHD cases, while the
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comes from a source covering the majority of GHD
cases in Sweden (KIMS comprise 95% of the patients
treated with Genotropin®; the market share for
Genotropin® during the study period was >70%). We
have assumed that the clinical characteristics, particularly
the severity of hypopituitarism expressed as the number
of pituitary hormone deficiencies, were comparable
between the cohorts. However, we cannot rule out that
the continuous improvements in other pituitary hormonal
replacement regimens may have additionally contributed
to better results in the KIMS cohort. Furthermore, the
data comprising untreated and treated groups, respect-
ively, reflect different time periods (1987–1992 vs 1995–
2007). The time difference is likely to be too small for sig-
nificant differences regarding mortality risks. Moreover, as
growth hormone replacement therapy in adults was not
authorised in Sweden until 1994, it is reasonable to assume
that the vast majority of patients considered untreated did
not receive GHT. An additional potential limitation is that
the cost-effectiveness results are country specific. How-
ever, the constructed model used for the economic eval-
uation is general and can easily be applied to other
countries as long as relevant input data are employed.
Recent evidence have demonstrated yet an additional
cause of GHD - traumatic brain injury (TBI), see, for in-
stance, the recent study by Tanriverdi et al [34]. The pro-
portion of TBI that caused GHD is low, however (1.8% of
the total KIMS dataset in 2003; [35]). Efforts should be
made in future studies to perform separate cost-
effectiveness calculations for different patient groups.
Growth hormone was approved in Sweden for treat-
ment in adults with pronounced growth hormone defi-
ciency in 1994, and, hence, our untreated patient group
by necessity consisted of those with GHD prior to 1994.
The best source of information for this group is the na-
tional registries. The majority of the patients included in
our untreated group have been diagnosed with pituitary
macroadenoma and undergone surgery [36]. GH defi-
ciency appears in about 95% of those patients [36]. The
limitations of this approach are (1) that no precise infor-
mation about the cause(−s) of GHD in the untreated
group is available, and (2) that different time periods
were compared (untreated 1987–1992, and treated
1995–2011). It may be that being untreated comes with
less severe health consequences during the latter period.
It cannot be neglected that progress in overall medical
treatment and improvement in clinical care may play a
certain role in patients’ survival.
In the treated group, the number of patients with iso-
lated GHD was small (n = 34; 7.8%). Thus, the size of
the treated group with isolated GHD and the lack of
clinical information about hypopituitarism in the com-
parator group (untreated) makes subgroup analysisimpossible. Almost 40% of patients (n = 171) had 1 or 2
additional to GH pituitary hormone deficits and 53% of
patients (n = 229) had panhypopituiatrism. With regard
to specific deficits 78% of patients had FSH/LH defi-
ciency, 73% - TSH deficiency, 64% - ACTH and 14% -
vasopressin. The majority of patients received hormonal
replacement as appropriate. Information about hypo-
pituitarism in the comparator group (untreated patients)
was not recorded in the hospital discharge registry.
Thus, we could not compare treated and untreated co-
horts in this respect. However, comparing the KIMS co-
hort with contemporary patients not in the KIMS cohort
demonstrates that the distribution of additional pituitary
deficits in the KIMS cohort resembles the overall distri-
bution in patients with hypopituitarism.
Conclusion
With global healthcare costs escalating, economic evalu-
ations are increasingly used to guide decision-making re-
garding the funding of new and available drugs. This
study fills a gap in the cost-effectiveness literature for
the use of GHT in adults with GHD, and suggests that it
is a cost-effective therapy in Sweden when considering
morbidity and mortality associated with GHD and the
impact on QoL.
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